Key Takeaways
- • OrbiMed has raised $3 billion in commitments across two new private equity funds focused on healthcare and life sciences in the U.S., Europe, and Asia.
- • OrbiMed Private Investments X raised more than $1.9 billion for U.S. and European life sciences venture capital opportunities.
- • OrbiMed Asia Partners VI raised more than $1 billion for healthcare growth equity and venture capital investments across Asia.
- • The firm manages more than $21 billion in assets, with the new funds expanding its investment capacity across private equity, public equity, and royalty and credit strategies.
- • Investors include medical institutions, university endowments, foundations, pension funds, sovereign wealth funds, and family offices, many of them long-standing backers.
Summary
OrbiMed has raised $3 billion in commitments across two new private equity funds focused on healthcare and life sciences investments in the United States, Europe, and Asia, according to the firm's announcement. OrbiMed Private Investments X raised more than $1.9 billion to invest in U.S. and European life sciences venture capital opportunities, while OrbiMed Asia Partners VI raised more than $1 billion for healthcare growth equity and venture capital investments across Asia.
Both funds will target companies across biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services. OrbiMed plans to back companies from early development through later growth stages. The firm cited the growing role of artificial intelligence in drug development and healthcare, the emergence of new therapeutic approaches, and China's expanding biotechnology industry as major trends shaping its strategy.
Investors in the new funds include medical institutions, university endowments, foundations, pension funds, sovereign wealth funds, and family offices. OrbiMed said the capital base includes many long-standing investors that supported the firm's previous healthcare strategies. Carl Gordon, Managing Partner of OrbiMed, said, "There has never been a more exciting time to invest in life sciences innovation." Carter Neild, also a Managing Partner, said the firm would "work tirelessly over the coming years to meet their high expectations."
OrbiMed is led by 20 partners and supported by more than 150 professionals with expertise spanning company incubation, strategy, operations, and finance, operating from 12 locations across major global healthcare markets. The new funds increase the firm's investment capacity as it manages more than $21 billion in assets. Its broader platform invests across private equity, public equity, and royalty and credit strategies, providing capital to healthcare companies ranging from startups to large multinational corporations.
Both funds will target companies across biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services. OrbiMed plans to back companies from early development through later growth stages. The firm cited the growing role of artificial intelligence in drug development and healthcare, the emergence of new therapeutic approaches, and China's expanding biotechnology industry as major trends shaping its strategy.
Investors in the new funds include medical institutions, university endowments, foundations, pension funds, sovereign wealth funds, and family offices. OrbiMed said the capital base includes many long-standing investors that supported the firm's previous healthcare strategies. Carl Gordon, Managing Partner of OrbiMed, said, "There has never been a more exciting time to invest in life sciences innovation." Carter Neild, also a Managing Partner, said the firm would "work tirelessly over the coming years to meet their high expectations."
OrbiMed is led by 20 partners and supported by more than 150 professionals with expertise spanning company incubation, strategy, operations, and finance, operating from 12 locations across major global healthcare markets. The new funds increase the firm's investment capacity as it manages more than $21 billion in assets. Its broader platform invests across private equity, public equity, and royalty and credit strategies, providing capital to healthcare companies ranging from startups to large multinational corporations.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.